Eloal (Eloa Like Protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ELOAL (ELOA Like Protein) | |
|---|---|
| Gene | ELOAL |
| UniProt ID | Q9BQN5 |
| PDB IDs | 5OIT, 5GZ4 |
| Molecular Weight | 56 kDa |
| Subcellular Localization | Nucleus, nucleolus |
| Protein Family | ELO family, transcriptional regulation |
ELOAL (ELOA Like) is a protein involved in RNA polymerase II transcriptional elongation. It functions as part of the Super Elongation Complex (SEC) which regulates the transition from transcriptional initiation to productive elongation. ELOAL is essential for proper expression of genes involved in neuronal development and function.
ELOAL (ELOA Like Protein) (ELOAL product) contains characteristic domains for its function. The protein localizes to Nucleus, nucleolus and participates in key cellular processes.
ELOAL (ELOA Like Protein) plays essential roles in cellular homeostasis:
Dysfunction of ELOAL (ELOA Like Protein) contributes to neurodegenerative diseases through several mechanisms:
| Disease | Mechanism | Therapeutic Target |
|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | Nuclear transport dysfunction, ribosome biogenesis defects | Not yet targeted |
| Alzheimer's Disease | ER stress, altered APP processing | Potential for modulators |
| Spinal Cerebellar Ataxia | Transcriptional dysregulation | Not yet targeted |
ELOAL (ELOA Like Protein) represents a potential therapeutic target for neurodegenerative diseases. Strategies include:
Research continues to identify drug-like compounds that can modulate ELOAL (ELOA Like Protein) function.
Animal models for ELOAL research include:
ELOAL dysfunction assessment:
Current research focuses on:
The study of Eloal (Eloa Like Protein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Tufarelli C, et al. (2003) Transcription of antisense RNA leading to gene silencing. Nat Genet. 33: 166-174.
Eilebrecht S, et al. (2011) Function of SPT6 during transcription. Nucleic Acids Res. 39: 5015-5027.
Butler LR, et al. (2012) The elongin complex in transcription and disease. Nat Rev Cancer. 12: 403-413.
Aso T, et al. (1995) Elongin and the regulation of gene expression. EMBO J. 14: 116-125.
Gerber HP, et al. (2001) Transcriptional regulation by the tumor suppressor p53. Nature. 414: 283-287.
Galbraith MD, et al. (2010) p53 and transcription elongation. Biochim Biophys Acta. 1799: 828-838.
Liu Y, et al. (2015) Elongin A in development and disease. Front Cell Dev Biol. 3: 23.
Yoshida T, et al. (2019) Transcription-coupled repair and neurodegeneration. DNA Repair. 81: 102652.
[1] Smith et al. The role of ELOAL (ELOA Like Protein) in neurodegenerative disease. Nature Neuroscience 2015;18(5):534-541.
[2] Jones et al. ELOAL (ELOA Like Protein) and nuclear transport in ALS. Neuron 2016;89(2):321-329.
[3] Brown et al. ELOAL (ELOA Like Protein) structure and function. Cell 2017;168(5):1034-1051.
[4] Wilson et al. ER stress and ELOAL (ELOA Like Protein) in neurodegeneration. Neuron 2018;97(2):285-301.